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ABSTRACT 
 
Direct cDNA preamplification protocols developed for single-cell RNA-seq have enabled transcriptome 
profiling of precious clinical samples and rare cells without sample pooling or RNA extraction. Currently, 
there is no algorithm optimized to reveal and remove noisy transcripts in limiting-cell RNA-seq (lcRNA-seq) 
data for downstream analyses. Herein, we present CLEAR, a workflow that identifies reliably quantifiable 
transcripts in lcRNA-seq data for differentially expressed gene (DEG) analysis. Libraries at three input 
amounts of FACS-derived CD5+ and CD5- cells from a chronic lymphocytic leukemia patient were used to 
develop CLEAR. When using CLEAR transcripts vs. using all transcripts, downstream analyses revealed 
more shared transcripts across different input RNA amounts, improved Principal Component Analysis 
(PCA) separation, and yielded more DEGs between cell types. As proof-of-principle, CLEAR was applied 
to an in-house lcRNA-seq dataset and two public datasets. When imputation is used, CLEAR is also 
adaptable to large clinical studies and for single cell analyses. 
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Deep sequencing of transcriptomes (RNA-seq) provides important insights into biology and disease. Bulk 
RNA-seq requires hundreds of thousands of cells. The resultant transcriptomic profile is therefore the 
average of cells at different transcriptomic states or even different cell types within the same tissues (e.g., 
infiltrating immune cells or normal cells in tumor samples). With the discovery of new genes and splice 
junctions in the first single-cell RNA-seq (scRNA-seq) study 1, researchers realized the need to profile 
single-cell transcriptomes. Coinciding with this intense interest is the development of diverse approaches 
to perform scRNA-seq, which have been summarized in recent reviews 2–5. Improvements in reagents that 
enable full-length transcriptome profiling by direct global amplification at the single-cell level (e.g., SMART-
seq 6–8, Quartz-Seq 9, and the ‘Tang’ method 1) have also enabled direct amplification for the analysis of 
groups of 10’s-100’s cells, i.e., limiting-cell RNA-seq (lcRNA-seq). 
 
The advantages of direct amplification are manifold. First, it lowers the barrier in identifying 
differentially expressed genes (DEGs) in rare cell populations. Until recently, researchers had to pool cells 
from multiple samples to extract quantifiable amounts of total RNA for library generation. With direct cDNA 
preamplification, the number of cells required for successful library preparation dropped below 100 cells, a 
level often achievable from just one sample.  Also, quantifying RNA accurately below 250 pg/μL is 
challenging. Direct cDNA preamplification eliminates this need by using cell counts (e.g., from fluorescence 
activated cell sorting (FACS) or laser capture) instead of RNA mass to standardize input amounts between 
experimental groups. Second, direct cDNA preamplification greatly preserves transcript quality by quickly 
transforming labile RNA into stable cDNA, as degradation associated with extraction can be significant. 
Third, direct amplification of enriched cells deposited into well-plates allows the incorporation of nanoliter 
microfluidics to deliver/mix reagents and templates quickly. This further preserves RNA integrity. 
 
Even with these advances, systems noise associated with transcript degradation is inevitable and 
requires computational solutions, especially if large numbers of replicates are not feasible. Current 
publications on lcRNA-seq data fall into two categories: cell-pool samples as part of method development 
or scRNA-seq methodology comparisons 6,10–12 and ultralow amounts of extracted RNA as input for RNA-
seq library preparation 13–15. Analysis workflows for bulk RNA-seq and scRNA-seq data are distinct as each 
approach addresses a different research question. The goal of bulk RNA-seq is to identify differences in 
transcriptomic profiles between treatment groups, whereas the goal of scRNA-seq is to characterize cell 
subpopulations in tissues or bulk cells. In this regard, the aim of lcRNA-seq experiments is like that of bulk 
RNA-seq experiments, whereas their data quality (e.g., prevalence of zero count genes or ‘dropout rate’ 
10,16,17) is similar to that of scRNA-seq. Therefore, statistical methods often used for between-group 
comparisons in bulk RNA-seq studies, such as the negative binomial distribution-based test in DESeq2 18, 
should not be used for lcRNA-seq data without modifications because they are susceptible to zero-count 
artifacts. On the other hand, the myriad of tools 19–28 for analyzing scRNA-seq data are tuned to work with 
high variabilities (e.g., true biological variations in single cells or variabilities due to cDNA preamplification) 
but require large numbers of replicates not possible in lcRNA-seq studies. 
 
 Here, we describe CLEAR, a computational preprocessing approach for between-group 
comparisons of lcRNA-seq experiments. Designed for low numbers of replicates, CLEAR focuses on 
identifying robust transcripts with even read coverage for downstream analysis to control for data noise. It 
examines the noise pattern of individual samples to identify ‘reliably quantifiable’ transcripts for maximal 
signal and minimal noise. CLEAR transcripts common to replicates across two comparison groups will be 
used for subsequent analyses. Using a dataset derived from the same RNA stock but at dilutions spanning 
typical lcRNA-seq inputs, we show that CLEAR greatly improves similarity between results from three input 
RNA levels. In two public datasets, we demonstrate that the numbers and dispersion patterns of CLEAR 
transcripts yield a novel way to evaluate library qualities. In an in-house murine neural cell lcRNA-seq study, 
utilizing CLEAR transcripts significantly improves cell type separations by Principal Component Analysis 
(PCA) and validations of cell phenotype markers. 
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RESULTS 
 
Developing CLEAR 
 
The experimental design for developing CLEAR is presented in Figure 1A. Our goal is to detect differences 
between two biological conditions using low input amounts and few replicates. Total RNA was extracted 
from FACS-derived primary CD5+CD19+ (CD5+) and CD5-CD19+ (CD5-) cells from a chronic lymphocytic 
leukemia (CLL) patient, thereby representing data quality typical of a clinical study. The RNA was diluted 
to levels found in typical lcRNA-seq projects with three replicates per input mass (10-, 100-, and 1,000-pg) 
and cell type. Although CLEAR is targeted for between-group comparisons in rare/limiting cell 
transcriptomes, sample inputs used for its development were from extracted RNA and not from cell pools. 
The overall design rationale is as follows: 1) To track the efficacy of transcripts selected by CLEAR in 
downstream DESeq2 18 analysis, the composition of input RNA had to be the same for all dilutions so that 
the only difference within the same cell type was the input amount; 2) The 10- and 100-pg input RNA levels 
approximate the RNA in ~5 and ~50 immune cells, respectively. The 1,000-pg input level represents a ‘gold 
standard’ to compare the 10- and 100-pg to, as systems noise from this RNA amount is considered 
acceptable 10. 
 
LcRNA-seq data quality from serial dilutions of the same RNA stock strongly depends on input 
mass and yields dissimilar DEGs when processed with a standard RNA-seq analysis pipeline 
 
Average read depth was 15.5 million clusters, which is typical of bulk mRNA-seq experiments. Post-
alignment quality assessment was used to illustrate the effect of input RNA amounts on data quality. As 
expected, quality parameters correlate inversely with RNA inputs (Figure S1), with the 10- and 100-pg 
samples yielding less transcriptomic information than the 1,000-pg samples despite having similar 
sequencing depths. 
 
To examine the effect of technical noise associated with lcRNA-seq experiments, we performed DEG 
analysis using a standard bulk cell RNA-seq workflow on the 10-, 100- and 1,000-pg replicates without 
consideration of noise structure from signal dropouts and RNA degradation. As expected, the overall 
transcript variabilities, depicted in Figure S2 as scatterplots between replicates of the two cell types, were 
highest in the 10-pg input RNA replicates. Within all samples, variabilities were highest in the low- to 
medium-expressed transcripts while the expression profiles converged at high-expressed transcripts. 
  
Next, we performed DEG analysis using DESeq2 workflow without modifications 18. DEG counts 
for the CD5+ vs. CD5- comparison were: 1,000-pg: 2,996, 100-pg: 744, and 10-pg: 898 (Figure 1B). This 
outcome is unexpected as the statistical power to discern DEGs should increase with increasing RNA input 
mass. Of the DEGs identified between the two cell types, few were shared between any two input levels 
(Figure 1C). This is also unexpected because the three input levels were diluted from the same RNA 
extraction stocks. In Figure 1D, we present PCA plots for cell type comparisons at the three input levels. At 
the 10-pg input amount, the gene expression profiles from the three CD5- replicates were vastly different 
from each other resulting in no separation between the cell types along either Principal Component 1 (PC1) 
or PC2. At the 100- and 1,000-pg levels, the transcriptome profiles distinguished the two cell types, with 
PC1 accounting for 26.3% and 74.6% of the variance, respectively. 
 
Taken together, the transcriptome profiles, the DEG dissimilarities and quantities, and the 
inconclusive PCA outcome reveal a high degree of systems noise at the 10-pg input level. Though systems 
noise was reduced at the 100- and 1,000-pg input amount, still relatively few shared DEGs were identified 
at these two levels. As such, lcRNA-seq data clearly require custom analysis to control for systems noise. 
 
Individual gene coverage profiles can guide selection of robust and reliably quantifiable transcripts 
in high noise conditions 
 
It is known that systems noise associated with lcRNA-seq data are highest in lowly-expressed transcripts 
and manifested as large amounts of duplicated reads 14,29. As our aim is to provide a DEG analysis workflow 
for studies/samples with degraded RNA (e.g., multi-step cell-type enrichment from stored samples),  low 
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RNA content (e.g., <100 immune cells), and few replicates, we elect to identify reliable transcripts in each 
replicate within each experimental group for between-group comparisons. The CLEAR workflow is 
presented in Figure 2A and in Methods. 
 
In Figure 2B, we illustrate CLEAR transcript evaluation using coverage profiles from three genes 
in a 10-pg CD5+ sample. The first, GAPDH, is a highly-expressed housekeeping gene. This group of genes 
has uniform 5’ to 3’ read coverage, similar to coverage profiles in bulk RNA-seq. The second gene, RPS7, 
is in the last accepted CLEAR transcript bin. At this point, coverage profiles switch from an acceptable 
unimodality centering at the middle of the transcript to an unacceptable amount of bi-modality with region(s) 
of read pile-ups and region(s) with low/no coverage. Lastly, DDAH2 is below the CLEAR threshold. Here, 
the profile is dominated by regions with drastically different coverage. These profiles are prone to erroneous 
gene expression quantifications and false DEGs. 
 
To illustrate the changes in coverage profiles, we plot the transcript coverage profile mean μi from 
CD5+ samples (one replicate per input level) in Figures 2C and 2D as scatter- and violin plots, respectively. 
The 100- and 1,000-pg samples have even read distributions (μi≈0) for the 6,000 highest expressed 
transcripts while the 10-pg transcripts experience unevenness after the 2,000th highest expressed 
transcript. The red line signifies the transition of transcripts passing CLEAR to transcripts too noisy for DEG 
analysis. Due to higher input amounts in the 100- and 1,000-pg samples, their acceptable-to-unacceptable 
transitions occur at lower expression levels not shown in the plots (see discussion below). 
 
CLEAR selection increases shared DEGs between CD5+ and CD5- samples at all RNA input levels 
and improves cell type separation at the 10-pg level 
 
Earlier in this report (Figure 1B-D; Figure S2), we presented the impact of systems noise associated with 
lcRNA-seq libraries. In Figures 3 and S3-S4, we present evidence for the transformative power of removing 
noisy transcripts from lcRNA-seq DEG analysis. First, we examine the impact of CLEAR on the number of 
robust transcripts per input level. The red histogram (Figure 3A, right plot) shows 12,246 shared transcripts 
passing CLEAR in all 1,000-pg samples (three replicates/cell type). The number drops to 4,983 for the 100-
pg samples and to 306 for the 10-pg samples. The high number of shared CLEAR transcripts among the 100- and 
1,000-pg samples signifies low system noise, while few CLEAR transcripts are shared among the 10-pg samples. This 
highlights that input amounts ⩽5 cells are susceptible to systems noise. The same trends are observed when the 
shared CLEAR transcripts are investigated separately by cell type (Figure S3). 
 
The effect of CLEAR on replicate-to-replicate comparisons is presented in Figure S4. The main 
takeaway is that CLEAR removes a large number of lowly-expressed transcripts from the 10-pg samples 
leaving highly-expressed transcripts for downstream analyses. The amount of retained transcripts 
increases with increasing RNA input. For the 1,000-pg samples, we observe transcripts from the entire 
transcription range passing CLEAR. This supports ours and others’ postulation 10 that the molecular 
complexity in 1 ng RNA approaches that found in bulk RNA-seq. We note subtle differences between each 
comparison pair, illustrating that CLEAR assesses samples independently to derive non-static cutoff values. 
 
The Venn diagrams in Figure 3B show the overlaps of CLEAR transcripts (depicted by the red bars 
in Figure 3A) common to all 6 samples (3 replicates/cell type) per input level. With CLEAR successfully 
excluding noisy transcripts from these lcRNA-seq data, nearly all of the shared CLEAR transcripts at each 
input level are contained in the shared CLEAR transcripts at the respective higher input level. 
 
Similarly, CLEAR pre-selection positively impacts the DEG analysis between cell types (Figures 
3C and 3D). In contrast to using all transcripts (Figure 1B; also Figure 3C inset), DEGs are now lowest 
(n=3) in the 10-pg comparison, intermediate (n=189) in the 100-pg comparison, and largest (n=2,826) in 
the 1,000-pg comparison. This trend is expected as power to detect DEGs increases with increasing RNA 
input. Also, CLEAR pre-selection alters the DEG overlap shown in Figure 1C. When only CLEAR transcripts 
are used (bottom Figure 3D), the 3 DEGs at the 10-pg inputs are: CD69 (found in all comparisons); SRSF11 
(also found in the 1,000-pg comparison); and HINT1 (only found in the 10-pg comparison). Of the 189 DEGs 
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at the 100-pg input level, a majority (n=135) is shared with the 1,000-pg input. These overlaps far exceed 
those using all transcripts (Figure 1C and top Figure 3D). 
 
Finally, applying CLEAR also improves PCA segregation of cell types (Figure 3E). In contrast to 
results from data without CLEAR selection (Figure 1D), the CD5+ replicates are now separated from the 
CD5- replicates along PC1 at all input levels (Figure 3E) instead of just at the 100- and 1,000-pg levels as 
in Figure 1D. 
 
To conclude, we remind readers that the dilution samples were prepared from the same RNA stock, 
the library generation was performed using the same reagents, by the same scientist, at the same time, 
and sequenced on the same flow cell. The dramatic differences in data quality observed in Figure 2C - 2D 
are mainly associated with the input RNA amount. While the traditional analysis shown in Figure 1 is 
severely hampered by the amount of systems noise in lcRNA-seq data, implementation of CLEAR results 
in overlapping and convergent DEGs at all input levels. 
 
The number of CLEAR transcripts correlates with authors’ quality measures in public scRNA-seq 
data 
 
To evaluate CLEAR’s utility in identifying robust transcripts in published ultralow-input full-length RNA-seq 
data, we selected an scRNA-seq dataset based on the Fluidigm/SMART-seq approach. Ilicic et al. 22 
provided detailed quality characteristics on captured single cells. We selected the mouse embryonic stem 
cells (576 cells grown in 2i or alternative 2i media) to compare CLEAR’s assessments of the captured cells 
vs. the authors’ quality calls of ‘Good’ and ‘Empty/No capture’. In Figure S5A, we present violin plots 
illustrating μi from scRNA-seq data from a ‘Good’ cell. We note that the coverage bifurcations observed in 
our lcRNA-seq data are also observed in the scRNA-seq data. In Figure S5B, we provide CLEAR transcript 
count distributions in the two quality-groups. For the 521 ‘Good’ cells, they have similar CLEAR transcript 
counts with mean of 4,098. The ‘Empty’ cells, however, have widespread CLEAR transcript counts with 
mean at 651 and with 10 of 15 cells having 0. As depicted, the mean value is skewed by two outliers, 
potentially due to ambient RNA from cell bursting prior to imaging. 
 
CLEAR transcript numbers are similar between studies with similar input RNA mass 
 
Next, we applied CLEAR to SMART-Seq data from Bhargava et al. 14 prepared from serial dilution (25-, 50-
, 100- and 1,000-pg) of polyA-selected mRNA from control and Activin A-treated mouse embryonic stem 
cells. Again, we note that the read coverage bifurcations observed in our lcRNA-seq data also occurred 
here (Figure S5C). Figure S5D presents CLEAR transcript counts for the four samples (control and treated 
groups, two replicates each) at all input levels. As expected, CLEAR transcript counts increase with 
increasing mRNA inputs. To compare CLEAR transcript counts in the Bhargava et al. 14 data to our 
CD5+/CD5- data, one should note the difference in type of input material (polyA-selected mRNA in the 
former and total RNA in the latter) and associated differences in sample preparation chemistry. We apply 
a conservative adjustment factor of 10 30 between total RNA and mRNA. As such, our 1,000-pg total RNA 
‘gold standard level’ is comparable to Bhargava et al.’s 14 100-pg mRNA input. Indeed, the Bhargava et al. 
14 100-pg mRNA libraries produced from Activin A stimulated cells had similar shared CLEAR transcript 
counts (mean, 14,940) to our 1,000-pg CD5+/CD5- replicates (mean, 14,717). It is worth noting, however, 
that the unstimulated control samples from the Bhargava study produced many fewer CLEAR transcripts 
(mean, 6,735), demonstrating the ability of CLEAR to distinguish active- and quiescent state between 
samples. At the intermediate input level of 100-pg total RNA, the closest corresponding level for the 
Bhargava et al. 14 study would be 10-pg mRNA. Since their lowest input level was 25-pg, it makes sense 
that their average CLEAR transcript counts of 6,408 are similar to our average transcript counts of 8,420 at 
100-pg input. Due to the higher RNA input amount, the data in the Bhargava et al. 14 study was not 
challenging enough to highlight CLEAR's ability to improve DEG and PCA analyses between the two 
biological groups, in agreement with the authors’ original assessment. 
 
CLEAR improves group separation of murine neural cell types and recapitulates genes known to 
be differentially expressed between them 
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To demonstrate the applicability of CLEAR in a biological system, we applied it to lcRNA-seq data derived 
from three cell types in murine hippocampal dentate gyrus (DG), a highly-studied neurogenic niche 
associated with memory and cognitive function 31. This region is of particular interest because resident  
stem and glial cells show robust morphologic and proteomic responses to a variety of injuries such as 
trauma and seizures 32,33. However, the stem cells and local glial populations are small cell populations 
embedded in a heterogeneous niche thereby perfect candidates for FACS-derived lcRNA-seq analysis. 
 
 The study schematics are shown in Figure 4A and the variability of CLEAR transcript counts in 
Figure 4B. The data reveal that neural progenitor cells had the highest number of CLEAR transcripts, 
followed by neural stem cells and then astrocytes. While this trend may reflect differences in cell size and 
RNA content, it may also reveal the tolerance of each cell type toward the cell dissociation and enrichment 
conditions. For example, astrocytes possess a complex branching of fine processes extending from their 
cell body that could be damaged during the mechanical dissociation and flow sorting. Furthermore, they 
are intrinsically reactive to changes in the external environment 34 such as the chemical dissociation step 
and the FACS media required by the Clontech SMARTer kit (phosphate-buffered saline devoid of fetal 
bovine serum, Ca2+, and Mg2+). 
 
Despite suboptimal cDNA quality from the astrocytes, the application of CLEAR greatly enhanced 
cell-type separations when compared to using all available transcripts (Figure 4C). When all transcripts 
were used, PCA plots show clear separation between stem cells and progenitors (third panel on top), but 
the lower transcript quality in astrocytes renders the discrimination between astrocytes and stem cells 
unclear (first panel on top). The astrocyte transcript quality does not impact its separation from the 
progenitors due to large differences in transcript profiles between these two cell types (second panel on 
top). Upon application of CLEAR, astrocytes and stem cells become well separated (first panel on bottom) 
while retaining separation between astrocytes and progenitors (second panel on bottom). 
 
Genes known to be differentially expressed in the three cell types (Table 1) are used to confirm the 
efficacies of the enrichment strategies and of the CLEAR analysis. Of the transcripts listed in Table 1, only 
the four shown in the top section and in Figure 4D passed CLEAR in all three cell types. Genes that failed 
CLEAR are presented in Figure S6. Glial fibrillary acidic protein (Gfap) and SRY-Box 9 (Sox9) are known 
to be higher in astrocytes and stem cells than in progenitors, which we also found (q < 0.01 and 0.0001, 
respectively). Glutamate ionotropic receptor NMDA type subunit 2C (Grin2c) and HOP homeobox (Hopx) 
are known to be different between stem cells and astrocytes, with Hopx higher in stem cells and Grin2c 
higher in astrocytes. Our findings confirmed both trends (q < 0.01 and q < 0.001, respectively). In addition, 
our data show that the expressions of Hopx and Grin2c are significantly higher in stem cells and astrocytes 
than in progenitors (q < 0.0001 for both). Finally, the expression of fatty acid binding protein 7 (Fabp7) is 
known to be higher in progenitors and stem cells relative to astrocytes as confirmed in our experiment (q < 
0.01 and q < 0.05, respectively). 
 
For genes that do not pass CLEAR, the picture is more nuanced. We examine normalized count 
plots for a few of the known discriminating transcripts (Figure S6). Inhibitor of DNA binding 4 (Id4) and  
SRY-Box 2 (Sox2) are known to have similar transcript levels in astrocytes and stem cells but higher than 
those in progenitors, which is what we found. Minichromosome maintenance complex component 2 
(Mcm2), doublecortin (Dcx), eomesodermin (Eomes), proliferating cell nuclear antigen (Pcna), neuronal 
differentiation 1 (Neurod1), and neurogenin 2 (Neurog2) have higher expressions in the progenitors 35–40, 
which we also find. However, nestin (Nes) is expected to be expressed in both stem cells and progenitors, 
but is only observed in the latter. Without CLEAR, Nes would be called as significantly higher in progenitors 
(q ≤ 0.01). With CLEAR, Nes fails its criteria thereby avoiding a false finding. Taken together, our dataset 
recapitulates and reinforces relative gene expression patterns reported for neural stem cells, progenitors, 
and astrocytes and shows that staining, sorting, and lcRNA-seq with CLEAR can be used to distinguish 
these cell types. 
 
DISCUSSION 
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Total RNA input amount for lcRNA-seq (e.g., 10 - 1,000-pg from 1 - 100 cells) is closer to amounts found 
in scRNA-seq studies (1 - 10-pg) than to bulk RNA-seq studies (100 - 200-ng). Due to the minute RNA input 
amount in single-cell/limiting-cell transcriptomic studies, the library generation process, with the exception 
of single-molecule sequencing, is preceded by global cDNA preamplification. Researchers have observed 
artefacts such as a large proportion of the sequencing reads being dominated by a small number of 
transcripts 14, excessive transcripts with zero read counts 41, high variabilities between and within replicates 
of sample groups 42, distortion towards shorter transcripts 43, and higher variances at lower biological 
abundances 10,11. Together, these artefacts result in noisy sc/lcRNA-seq data that challenge assumptions 
fundamental to bulk RNA-seq analysis approaches and render them unsuitable for direct application to 
these data 16. Existing strategies to overcome challenges associated with noisy data to uncover biological 
differences in single-cell studies include: 1) identifying low-quality, high-noise samples and removing them 
from downstream analyses 22; 2) applying transcript normalization 16,24,26,44; 3) incorporating ERCC spike-
in control 42,45; 4) utilizing median absolute deviation (more resistant to outliers) to characterize statistical 
dispersion 12; 5) integrating UMIs to track transcripts by molecular counts 46. Yet, due to the often low 
number of replicates and the goal of identifying DEGs between sample groups, the strategies for scRNA-
seq data just described are not appropriate or adequate for lcRNA-seq data. 
 
In this paper, we describe CLEAR, an objective approach to identify transcripts in lcRNA-seq with 
acceptable systems noise for downstream analyses. CLEAR requires transcripts to be reliably quantifiable 
in all replicates within and across comparison groups. This criterion is made possible due to the RNA quality 
preservation effects of direct cDNA preamplification reagents and library generation using nanoliter-
microfluidics devices as they increase even read coverage in lcRNA-seq transcripts. 
 
To our knowledge, preprocessing lcRNA-seq data using CLEAR followed by DEG analysis is 
unique and unlike approaches used by others in similar studies. For example, Shanker et al. 13 performed 
Pearson correlation comparisons between serial dilutions of input RNA vs. their 1 μg input control using 
log2 of median RPKM for all genes having ≥ 2 reads coverage.  Bhargava et al. 14 performed DESeq without 
prior data preprocessing to compare the performance between three library preparation methods as well 
as within serial dilutions of mRNA derived from two mouse embryonic stem cell culture conditions. Liu et 
al. 47 utilized relative expression orderings to harmonize clinical transcription signatures between low-input 
and bulk RNA-seq libraries. In contrast, CLEAR comprehensively screens all transcripts in all replicates 
within an lcRNA-seq study for genes with even coverage for downstream analyses. The combination of 
characterizing each transcript by its read distribution mean μi followed by cutoff selection defined by 
expression across the full transcript distribution is deliberate. For any given transcript, even one with low 
systems noise, there are many reasons why its mean μi could deviate from zero: 1) transposase-based 
library generation methods 48 less effectively ‘tagment’ the 5’-end of transcripts (3’-ends are less affected 
likely due to the presence of poly(A) tails), affecting 5’-end read coverage; 2) transcript isoforms skew the 
read distribution along the length of the transcript, especially when prominent isoforms are not correctly 
annotated 17; 3) presence of truncated, polyadenylated RNA fragments/intermediates part way through the 
RNA decay pathway 49; 4) presence of RNA fragments with alternative polyadenylation sites 17,50,51. Thus, 
a non-zero μi alone does not signify a noisy transcript. Conversely, read coverage profiles of some of the 
noisy transcripts can become random and μi  can approach zero by chance. Simply keeping transcripts 
with a mean μi close to zero would result in some valid transcripts being excluded and some noisy 
transcripts being included. By characterizing the entire distribution of μi over a defined range of expression 
levels, outliers due to the above-mentioned effects do not impact the classification of that particular 
expression bin. In this manner, CLEAR adapts to the quality of each sample to assess systems noise, an 
approach more precise than using an arbitrary cutoff.   
 
In this report, we have selected two sets of public data 14,22 and one set of in-house data to illustrate 
the utility of CLEAR. One of the goals for using external datasets was to ascertain that the mean 
read/fragment distribution phenomenon observed in the CLEAR development data is also present in sc- 
and lcRNA-seq libraries derived from Fluidigm C1 IFCs and manual SMART-seq, respectively. As 
suspected, the violin plots from the public data (Figures S6A, and S6C) illustrate the distribution of μi 
transitions from an acceptable distribution centered around 0 to an unacceptably broad/bimodal distribution. 
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Another goal was to evaluate the ability of CLEAR to identify noisy transcripts in a broad range of datasets. 
The application of CLEAR to Ilicic et al. scRNA-seq data 22 revealed association between cell integrity and 
the resultant data quality. Figure S5B displays violin plots of the dispersion of CLEAR transcripts which 
recapitulated the authors’ microscopy assessments of intact ‘single cells’ and ‘no cell’. When applied to 
Bhargava et al. data 14,22, CLEAR identified increasing amounts of ‘passed’ transcripts with increasing 
mRNA input mass (Figure S5D) which we also observe in the CD5+/CD5- data. Together, these 
assessments confirm that CLEAR can independently reveal sample/transcript quality and identify noisy 
data associated with empty wells (Ilicic et al. data 14,22) and increases in data quality with increasing levels 
of RNA input (Bhargava et al. data 14,22). As yet another example of CLEAR's performance, we incorporated 
a proof-of-principle experiment with cells isolated from the neurogenic niche in murine hippocampus. 
Traditionally, this study has been hampered by limited numbers of stem cells and progenitors present in 
murine DG. By coupling preamplification-based lcRNA-seq with CLEAR, DEGs between these cell types 
can be achieved with only one mouse brain per biological replicate. 
 
When comparing different biological groups it is possible that a gene is highly expressed in one but 
not in the other. An example of this is depicted in the Eomes gene in Figure S6. It passes CLEAR in the 
progenitors but fails in the other cell types. While true DEG analysis is not possible for such genes, one can 
still use the CLEAR cutoff expression level (the count of the lowest transcript passing CLEAR for a particular 
sample) to report a bound on the fold change of such a gene consistent with the CLEAR analysis. For 
example, DESeq2 reports a log2 fold change of 8.97 when comparing the expression of Eomes of 
progenitors to astrocytes. However, the ‘bound’ procedure suggests a more modest difference of 1.48, 
when substituting the threshold for the featureCounts-reported expression value. The latter analysis is likely 
more reliable than the higher fold change reported by DESeq2 alone due to the presence of signal dropouts 
when all transcripts are used. 
 
 Although CLEAR can be applied to scRNA-seq data just as effectively as lcRNA-seq data (Figure 
S5A-B, results from analyzing Ilicic et al. 22 scRNA-seq data using CLEAR), the low complexity and highly 
variable nature of scRNA-seq data would typically result in insufficient CLEAR transcripts for meaningful 
DEG analysis, especially when requiring transcripts to pass CLEAR criterion in all (usually of a very large 
number) cells. The incorporation of imputation would relax the CLEAR criterion thereby rendering it useful 
in scRNA-seq data.  
 
In summary, utilizing a direct cDNA amplification approach, the lcRNA-seq strategy allows 
researchers to perform global transcriptome profiling and identify DEGs using a few cells. We develop the 
CLEAR algorithm around two prevalent phenomena in ultralow input RNA-seq data: 1) systems noise due 
to global preamplification of low RNA amount is more prevalent in medium- to lowly expressed transcripts; 
2) the read coverage profile of noisy transcripts contain discernible coverage gaps instead of even coverage 
along the transcript length. By gauging the average read coverage profile mean μi in transcripts binned by 
gene expression levels, CLEAR is able to systematically identify transcripts with sufficient integrity in all 
replicates across comparison groups for downstream analyses. Lastly, we note that by displaying μi  as 
violin plots, CLEAR is useful as a visual QC tool to eliminate or set aside data from scRNA-seq samples 
that fail at the cell enrichment stage or during library generation. In all, we highlighted the functionalities 
CLEAR brings to sc/lcRNA-seq data preprocessing and data quality visualization and hope to spark 
additional computational and statistical development in this area. 
 
 
METHODS 
 
CLL Patient Sample Acquisition  
A chronic lymphocytic leukemia (CLL) patient sample was obtained from the Leukemia Tissue Bank (LTB), 
a shared resource of the NCI-funded OSU Comprehensive Cancer Center. The sample was obtained 
following written informed consent in accordance with the Declaration of Helsinki and under a protocol 
reviewed and approved by the Institutional Review Board of the Ohio State University.  The patient had 
CLL as defined by the IWCLL 2008 criteria. The patient's white blood cells were isolated by Ficoll density 
gradient centrifugation (Ficoll-Paque Plus, Amersham Biosciences, Little Chalfont, UK) and samples were 
banked at -180°C in liquid nitrogen. Frozen cells were thawed and washed with RPMI 1640 media (Gibco, 
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Life Technologies, Grand Island, NY, USA) and resuspended at 5 × 106 cells/mL in complete medium 
containing 10% fetal bovine serum (FBS) (Sigma, St Louis, MO, USA), 2 mM l-glutamine, penicillin 
(100U/mL), and streptomycin (100 µg/ mL) (Gibco). 
 
Animals for Neural Cell Type Analysis 
All procedures involving animals were approved by the Ohio State Institutional Animal Care and Use 
Committee in accordance with institutional and national guidelines. Nestin-GFP mice were provided by 
Grigori Enikolopov at Cold Spring Harbor Laboratory52. All mice were housed in a 12 hour light-dark cycle 
with food and water ad libitum. For isolation of the dentate gyrus (DG), adult mice (6-9 wk old) were 
anesthetized with an intraperitoneal injection of ketamine (87.5 mg/kg) and xylazine (12.5 mg/kg) before 
perfusion with PBS. Following perfusion, the brain was removed and placed in cold Neurobasal A medium 
(Gibco 10-888-022) on ice. After bisecting the brain along the midsagittal line, the cerebellum and 
diencephalic structures were removed to expose the hippocampus. Under a dissection microscope (Zeiss), 
the DG was excised using a beveled syringe needle and placed in ice cold PBS without calcium or 
magnesium (Gibco 10-010-049). DGs from mice were first mechanically dissociated with sterile scalpel 
blades and then enzymatically dissociated with a pre-warmed papain (Roche 10108014001)/dispase (Stem 
Cell Technologies 07913)/DNase (Stem Cell Technologies NC9007308) (PDD) cocktail at 37°C for 20 min. 
Afterwards, the tissue was again mechanically disrupted by trituration for 1 min. Dissociated cells were 
collected by centrifugation at 500g for 5 min. 
 
Fluorescence activated cell sorting (FACS)  
For the human sample all cells were stained and sorted by FACS Aria (BD Biosciences, San Jose, CA, 
USA). Live CLL B cells (CD5+CD19+) and normal B cells (CD5-CD19+) were sorted from the patient 
sample. Briefly, cells for FACS were resuspended in PBS without calcium/magnesium and filtered through 
a 35µm nylon filter and then stained for PE-conjugated CD45 (HI30), PerCp Cy-5.5-conjugated CD19 
(HIB19), and Alexa Fluor 700-conjugated CD3 (UCHT1) monoclonal antibodies. Nonviable cells were 
excluded by the LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (Life Technologies, Carlsbad, CA, USA). 
Appropriate fluorescence minus one controls were used to determine nonspecific background staining. 
Single-cell gates were used to exclude the possibility of doublet cells. The FACS parameter diagrams for 
this process are available in Figure S7. 
 
For the Nestin-GFP mouse samples, cells were resuspended in PBS without calcium/magnesium 
and filtered through a 35µm nylon filter before staining with the following antibodies: O4-APC (1:100, R&D 
FAB1326A), O1-eFluor660 (1:100, Thermo Fisher/eBioscience, Pittsburgh, PA, 5065082), GLAST-PE 
(1:50, Miltenyi Biotec, Bergisch Gladbach, Germany, 130-098-804), CD45-APC (1:100, BD Biosciences, 
Franklin Lakes, NJ, 561018), CD31-APC (1:100, BD Biosciences, Franklin Lakes, NJ, 561814). Cells were 
incubated with antibodies on ice for 30 minutes. During the last 10 minutes of staining, Hoechst dye 
(1:10,000, Thermo Fisher, Pittsburgh, PA, 33342) was added for live/dead discrimination. All cells were 
washed twice following staining and immediately sorted as stem, progenitor, or astrocyte populations based 
on fluorescent markers with the FACSAria III (BD Biosciences, Franklin Lakes, NJ). CD31, CD45, O1, and 
O4 negative live cells were designated as stem cells if double positive for GLAST and GFP, progenitors if 
only GFP positive, and astrocytes if only GLAST positive. For cells in the limited cell number study, 50 cells 
were sorted into 96 well format plate for downstream lcRNA-seq library generation. 
 
Total RNA Extraction 
Total RNA extraction was performed using Trizol reagent (Invitrogen, Carlsbad, CA). Briefly, approximately 
two million FACS-derived CD5+ and CD5- cells were separately sorted into 1.7 ml microcentrifuge tubes. 
Excess buffer was removed by centrifugation. Trizol reagent was added to cell pellets and the extraction 
protocol recommended by Invitrogen was followed. Total RNA was precipitated with 10μg glycogen 
(Qiagen, Hilden, Germany). The quality of the total RNA was assessed with the Agilent 2100 Bioanalyzer 
(Agilent, Inc., Santa Clara, CA) using total RNA Pico chip. 
 
Library Generation and Sample Sequencing 
Total CD5+ and CD5- RNA quantified using the Invitrogen Qubit RNA HS Assay kit (Invitrogen, Carlsbad, 
CA) was serially diluted to masses characteristic of single- and limiting-cell RNA-Seq (10-, 100-, and 1000-
pg). The Clontech SMARTer v4 kit (Takara Bio USA, Inc., Mountain View, CA) was used for global 
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preamplification of these serially diluted samples in triplicate and also for direct global preamplification in 
FACS-derived murine DG cell types prior to library generation in quadruplicates with the Nextera XT DNA 
Library Prep kit (Illumina, Inc., San Diego, CA).  Samples were sequenced to a depth of 15 - 20 million 
2x150 bp clusters on the Illumina HiSeq 4000 platform (Illumina, Inc., San Diego, CA). 
 
Publicly Available Data Retrieval 
Published data was retrieved in FASTQ format from the following accession numbers: ArrayExpress E-
MTAB-2600 53 (mouse embryonic stem cells from 2i and alternative 2i media) and GSE50856 14 (SMART-
seq samples). 
 
Data Preprocessing, Alignment, and Quantification 
Individual FASTQ files were trimmed for adapter sequences and filtered for a minimum quality score of Q20 
using AdapterRemoval v2.2.0 54. Preliminary alignment using HISAT2 v2.0.6 55 was performed to a 
composite reference of rRNA, mtDNA, and PhiX bacteriophage sequences obtained from NCBI RefSeq 56. 
Reads aligning to these references were excluded in downstream analyses. Primary alignment was 
performed against the human genome reference GRCh38p7 or mouse genome reference GRCm38p4 
using HISAT2. Gene expression values for genes described by the GENCODE 57,58 Gene Transfer Format 
(GTF) release 25 (human) or release M14 (mouse) were quantified using the featureCounts tool of the 
Subread package v1.5.1 59 in unstranded mode. 
 
Sequencing and Alignment Quality Control 
Quality control was performed using a modification of our custom workflow QuaCRS 60. In brief, aligned 
read quality was verified using RNA-SeQC 61 and RSeQC 62. Parameters evaluated included the exonic 
rate (the percentage of reads aligning to exons), the intronic rate (the percentage of reads aligning to 
introns), and the duplication rate (the percentage of reads that were identified as PCR duplicates). 
 
Coverage Profiling 
Coverage depths across the aligned reference were calculated with a per-base resolution using the 
‘genomecov’ utility of Bedtools v2.27.0 63 in BedGraph format. It is imperative to utilize ‘split output’ mode 
to reduce the size of the output BedGraph files. These files are used as input into CLEAR. 
 
Calculation of Transcript μi 
For each transcript i annotated in the NCBI RefSeq GRCh38 reference sourced from the UCSC Genome 
Browser 64, CLEAR calculates the transcript’s μi parameter. This quantifies the distribution of the positional 
mean of the read distribution along that transcript between the 5’ (μi = -1) and the 3’ (μi = +1) ends (Equation 
1): 
 
 (1) 
$\mu_i = \frac{2}{L_{\mathrm{transcript}}}\left( \frac{\sum_{k=0}^{L_{\mathrm{transcript}} - 1} \left( k\cdot 
d_k \right) }{\sum_{k=0}^{L_{\mathrm{transcript}} - 1} \left(d_k\right) } \right) - 1$ 
 
where Ltranscript is the length of a given transcript, and dk is the coverage of exonic locus k zero indexed and 
starting at the transcription start site.  
 
Determination of Analysis-Ready CLEAR Transcripts 
All transcripts quantified by featureCounts are sorted by overall length-normalized expression. Histograms, 
of μi values from 250 transcripts each, are collected and fit using the optimize module of the Python scipy 
package, to a double-beta distribution as described by Equation 2: 
 
(2) 
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$H \left( \frac{(1+x)(1-\frac{1}{2}(1+x))^{1+b}}{2B(2, 2+b)} + \frac{(1+x)^{1+a}(1-\frac{1}{2}(1+x))}{2^{1+a} 
B(2+a,2)} \right)$ 
 
where H is a normalization parameter fixed by the bin sizes, B(q,p) is the beta integral of q and p, and x is 
the bin location. The fitting parameters are a and b, which are each bounded to be non-negative. A value 
of 0 for both parameters represents a symmetric distribution and positive values represent progressively 
bimodal distributions to the positive (a), or negative (b) direction. These windows are advanced in units of 
10 transcripts, reducing computational intensity. Once a window is found where a or b have a value greater 
than 2, the software exports transcripts with a measured expression higher than that bin’s value for analysis. 
For multi-sample comparisons, transcripts are overlapped and only transcripts found in all samples are 
included for downstream analysis. 
 
CLEAR Visualizations 
A core component to the quality control of the CLEAR selection process is the visualization of μi to confirm 
that the characteristic bifurcation is observed. Violin plots are produced using code included with CLEAR 
which utilizes the matplotlib package in Python. Examples of this can be seen in Figures 2D, S5A, and S5C. 
 
DEG Comparisons 
Differentially expressed genes were called using DESeq2 18 run on counts tables generated with 
featureCounts as described above. In all summarization figures, a false discovery rate (FDR) q-value of 
<0.05 was used as an inclusion criterion for DEGs. 
 
Principal Component Analysis 
Principal component analysis (PCA) was utilized to visualize differences between samples. All PCA plots 
were generated from counts tables that were size-normalized and r-log transformed after CLEAR selection 
using methods included with DESeq2. Each comparison was processed with the SciKitLearn 65 PCA 
implementation and plotted using custom scripts in Python. 
 
Data Availability 
All original sequencing files have been deposited to Gene Expression Omnibus (GEO) under accession 
numbers GSE115032 (human CD5+ and CD5- data) and GSE115033 (mouse neural data). 
 
Code Availability 
The reference Python code implementing CLEAR is available for download at 
https://github.com/rbundschuh/CLEAR under the GPL3 license. 
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TABLES AND FIGURES 
 
 
 
Figure 1. lcRNA-seq analyses between sample groups without application of CLEAR. A) Workflow 
for total RNA extraction and QC analysis from FACS-derived CD5+ and CD5- CLL cells as input for lcRNA-
seq library generation for the development of CLEAR; B) The DEG counts as determined by DESeq2. 
Contrary to expectation, the 10-pg input has more DEGs than the 100-pg input replicates; C) Shared DEGs 
between the three input groups showing more DEGs that are unique than shared; D) Unsupervised analysis 
of CD5+ and CD5- samples by total RNA input amount. PCA reveals sample replicates separated by 
biological groupings at the 1,000- and the 100-pg input level but not at the 10-pg level. CLL: Chronic 
Lymphocytic Leukemia; PBMC: Peripheral Blood Mononuclear Cells; FACS: Fluorescence Activated Cell 
Sorting; BioA: Agilent Bioanalyzer RNA assay; DEGs: Differentially Expressed Genes; PC: Principal 
Component. 
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Figure 2. CLEAR Workflow: bin-based coverage analysis by transcript expression. A) Data analysis 
workflow using CLEAR to preprocess lcRNA-seq data. Step 1: Trimmed lcRNA-seq reads are aligned to 
the reference genome; Step 2: μi, the mean of the positional distribution of aligned reads along each 
individual transcript, is determined; Step 3: Transcript positional means, μi, (y-axis) are ranked and then 
binned by the transcript read coverage (x-axis). When μi of a bin is ≈ 0, the read distribution is symmetrical 
along the length of the transcript. When μi within a bin develops a bimodal distribution with a mode toward 
+1 (TTS) and -1 (TSS), its values will deviate from 0; Step 4: All available transcripts, binned into groups of 
250 are fitted to a bimodal distribution model. The emergence of a bimodal distribution identifies when 
aggregate μi start to deviate from a unimodal distribution around the center of the transcripts, indicated by 
a change in the fitting parameters a and b; Step 5: When either of the model parameters exceed a value of 
2 (indicated by a gray line), transcripts beyond that point are excluded by CLEAR for differential gene 
expression and other downstream analysis; Step 6: CLEAR transcripts are used in downstream between-
group analyses such as hierarchical clustering; B) example lcRNA-seq read coverage plots. Read coverage 
plot for GAPDH depicts a transcript with μi  ~ 0, RPS7 depicts a transcript close to the CLEAR cutoff, while 
DDAH2 depicts a transcript deemed too noisy by CLEAR; C) CLEAR profiles for 10-, 100- and 1,000-pg 
input mass lcRNA-seq data. The value of μi is plotted for the 7,000 highest expressed primary transcripts 
for three representative samples. The red line depicts the CLEAR filtering threshold; D) violin plots of the 
same data as shown in Figure 2C. The end marks indicate the window extrema and the middle bar indicates 
the mean. 
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Figure 3. lcRNA-seq analyses between sample groups after application of CLEAR. A) CLEAR 
transcripts shared between samples of each input mass group. The red bars depict the number of CLEAR 
transcripts found in all 6 samples (replicates in both CD5+ and CD5- groups); B) Left: CLEAR transcripts 
overlap between 10-pg and 100-pg input mass samples; Right: CLEAR transcripts overlap between 100-
pg and 1,000-pg input mass samples; C) DEG counts between CD5+ vs. CD5- cell types using only the 
shared CLEAR transcripts. The inset shows the data from Figure 1B without the application of CLEAR; D) 
Bottom: Overlap of DEGs from the 100-pg and 1,000-pg inputs (top repeats data from Figure 1C without 
CLEAR); E) PCA plots separating CD5+ and CD5- groups for all input masses using only CLEAR transcripts 
(inset repeats data from Figure 1D without CLEAR). PC: Principal Component. 
 
 
 
 
Figure 4. Application of CLEAR to a mouse neural lcRNA-seq experiment. A) Schematic of cell 
isolation and preparation for sequencing. The dentate gyri of Nestin-GFP mice were microdissected and 
dissociated into a single cell suspension. Cells were labeled with fluorescently conjugated antibodies 
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against markers for specific populations of cells present in the hippocampus. GFP+GLAST+ stem cells, 
GFP+GLAST- progenitor cells and GFP-GLAST+ astrocytes were isolated from live cells that were negative 
for microglial, oligodendroglial and endothelial markers. SMART-seq libraries were generated from these 
sorted cells; B) The means and ranges of CLEAR transcripts from each cell type (4 biological replicates 
per group). All groups are significantly different when compared using a t-test (p<0.01); C) PCA analyses 
by murine neuronal cell types. Top Panels: PCA plots using all available transcripts; Bottom Panels: PCA 
plots using only CLEAR transcripts; D) Normalized DESeq2 transcript counts for 4 genes that pass CLEAR 
and are known to be differentially expressed in murine neural stem cells, progenitors and astrocytes are 
used to confirm the identity of the cell populations derived from the staining and FACS strategies used to 
enrich these three cell populations. Boxplots: orange line, mean CLEAR transcripts for four biological 
replicates per neural cell type; whiskers: displaying 1.5X the inter-quartile range (IQR) beyond the first and 
the third quartiles; circles: outliers. FACS: Fluorescence Activated Cell Sorting; PC: Principal Component. 
 
 
 
 
Table 1. Application of CLEAR and DESeq2 to murine DG cell type comparisons. Genes known to be 
differentially expressed in murine astrocytes, stem cells and progenitors. lcRNA-seq data were 
preprocessed using CLEAR prior to between-group comparisons using DESeq2. Differential gene 
expression analysis evaluates the effectiveness of staining and FACS strategies in enriching these three 
cell types.  The bisecting line indicates the border between transcripts which pass CLEAR in all samples 
and those that do not pass CLEAR in all samples. Each comparison was processed using DESeq2 and the 
significance of the comparison is given. q: FDR-corrected p-values; N.S. (Not Significant), F.C. (Failed 
CLEAR), * (q ≤ 0.05), ** (q ≤ 0.01), *** (q ≤ 0.001), **** (q ≤ 0.0001). 
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Figure S1. Survey of quality control (QC) metrics of RNA-Seq data. All sequencing was subject to                
quality control as described in ​Methods ​. Key metrics are summarized here. Notably, in many metrics               
such as Intergenic Rate, Alignment Rate, and Duplication Rate, the 10-pg groups indicate lower quality               
libraries than 100-pg and 1000-pg. “Top30” corresponds to the proportion of reads that belong to the 30                 
highest genes by expression. Boxplots: orange line, mean metric value; whiskers: displaying 1.5X the              
inter-quartile range (IQR) beyond the first and the third quartiles; circles: outliers. 
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Figure S2. Between-sample correlations of detected RNA-Seq read counts. ​Scatter plots are drawn             
comparing each sample to each other sample for each input mass. 10-pg samples show much more                
scattered counts, whereas 100-pg and 1000-pg samples show progressively higher correlation. 
 
 
 
 
Figure S3. Comparison of overlapping transcripts. The analysis from Figure 3A was repeated,             
although CD5- and CD5+ samples were considered separately. Notably, the trend between CD5+ and              
CD5- mirrors that of the pooled data in Figure 3A. 
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Figure S4. CLEAR Filtering results in fewer noisy transcripts at the 10-pg sample level. Analysis               
from Figure S2 was repeated using CLEAR-filtered gene counts. Notably, 10-pg samples are observed to               
be sparser, while the remaining data points are of much higher correlation.  
 
 
 
 
 
Figure S5. Application of CLEAR to public datasets. A-B) ​Data from Ilicic et al.​22 was processed using                 
the CLEAR pipeline; ​C-D) Data from Bhargava et al.​14 was processed using the CLEAR pipeline; ​A) ​An                 
example CLEAR trace from released data shows a representative separation; ​B) ​CLEAR transcript             
identity allows the separation of cells the authors classified as “Empty” from those classified as “Good.” ​C)                 
An additional example trace; ​D) CLEAR transcript counts are indicative of the input mRNA mass used to                 
generate a sequencing library. 
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Figure S6. Neuronal cell type markers which did not pass the CLEAR criterion. Similar to Figure 4D,                 
for each remaining gene, expression was plotted using the raw counts. Individual cell types which passed                
CLEAR filtering are indicated with an asterisk (*) below the respective box plot. Boxplots: orange line,                
mean CLEAR transcripts for four biological replicates per neural cell type; whiskers: displaying 1.5X the               
inter-quartile range (IQR) beyond the first and the third quartiles; circles: outliers. 
 
 
Figure S7. FACS parameter diagrams for the enrichment of CD5+ and CD5- cells from a CLL 
patient PBMC sample. ​FACS flow diagrams depicting the steps involved in the enrichment of CD5+ cells 
and CD5- cells from live CD45+, CD3-, CD33-, CD19+ cells, followed by separation into either CD5+ or 
CD5- collection tubes (Figure 1). FACS: Fluorescence Activated Cell Sorting. 
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